A5045136677- Diabetes Treatment and Management
- Diabetes Management and Research
- Metabolism, Diabetes, and Cancer
- Medication Adherence and Compliance
- Pharmaceutical Practices and Patient Outcomes
- Diabetes and associated disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Chronic Disease Management Strategies
- Cardiovascular Function and Risk Factors
- Renin-Angiotensin System Studies
- Pharmacology and Obesity Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pancreatic function and diabetes
- Gastric Cancer Management and Outcomes
- Ion Transport and Channel Regulation
- Bariatric Surgery and Outcomes
- Hormonal Regulation and Hypertension
Novo Nordisk (United States)
2017-2025
Wilmington University
2021
Cooper Clinic
2018
To assess the association between remaining persistent with once-weekly glucagon-like peptide-1 receptor agonists (OW GLP-1 RAs) and risk of major adverse cardiovascular events (MACE) among patients type 2 diabetes mellitus (T2DM) atherosclerotic disease (ASCVD). We used Optum Research Database to identify who initiated OW RAs 1/1/2018-11/30/2022. Patients were classified as or non-persistent depending on whether there was a ≥ 60-day gap in medication supply after they continuously for first...
Background: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results (LEADER) clinical trial demonstrated that liraglutide added to standard-of-care (SoC) therapy for type 2 diabetes (T2D) with established cardiovascular disease (CVD) or elevated (CV) risk was associated lower rates death from CVD, nonfatal myocardial infarction (MI), stroke than SoC alone. Objective: objective this study assess the cost-effectiveness (CE) budget impact vs T2D patients CVD...
Bringing patients with type 2 diabetes to recommended glycated hemoglobin (HbA1c) treatment targets can reduce the risk of developing diabetes-related complications. The aim present analysis was evaluate short-term cost-effectiveness once-daily liraglutide 1.8 mg vs lixisenatide 20 μg as an add-on metformin for in US by assessing cost per patient achieving HbA1c-focused and composite targets.Percentages were obtained from LIRA-LIXI trial, which compared efficacy safety failing achieve...
The efficacy of once-weekly (OW) glucagon-like peptide-1 receptor agonists (GLP-1RAs) has been established in several trials people with type 2 diabetes mellitus (T2DM); however, real-world evidence on their effectiveness is limited. This study evaluated the OW GLP-1RA regarding glycemic and weight outcomes, relative to DPP-4i a comparator analysis. observational cohort glycated hemoglobin (HbA1c) outcomes T2DM two or more prescription claims for same using pre-post design (including...
This study compared the clinical and economic outcomes of long-term use liraglutide versus sitagliptin for treatment type 2 diabetes (T2DM) in real-world practice USA. We identified adult patients (≥ 18 years old) with T2DM who initiated or 2010–2014 using a large claims database. Quarterly glycemic control measures annual healthcare costs were assessed during 1st 2nd persistent medication use. Their associations (liraglutide sitagliptin) estimated multivariable regression models adjusted...
OBJECTIVE Despite the demonstrated benefits of glucagon-like peptide 1 (GLP-1) receptor agonist therapy, adherence and persistence with this therapy is often challenging. The purpose study was to expand current understanding patients’ experiences, motivations, challenges relevant their GLP-1 therapy. DESIGN AND METHODS This noninterventional, cross-sectional, qualitative used face-to-face interviews 36 adults type 2 diabetes who had been treated at least one medication. Inclusion criteria...
Abstract Purpose The purpose of this study was to evaluate patient, prescriber, and dose characteristics changes in glycated hemoglobin (HbA 1c ) for patients prescribed once weekly semaglutide diabetes (OW sema T2D). Methods This a retrospective claims-based using the Optum Research Database. sample included adult who had at least one claim OW T2D between Jan 1, 2018, Dec 31, 2019, were continuously enrolled health plan diagnosis type 2 (T2DM) during pre-index or post-index periods....
Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in patients with type 2 diabetes (T2D), but treatment discontinuation without new T2D therapy initiation may compromise outcomes.This retrospective cohort study (July 1, 2012, to December 31, 2019) identified ≥ 18 years the Optum® Clinformatics® Data Mart who discontinued liraglutide (index date). Patients continuous enrollment for 12 months before and after (baseline), 6 coverage pre-index, no start during...
A symposium at the 2023 American Thoracic Society (ATS) International Conference featured research on predictors of chronic obstructive pulmonary disease (COPD) occurrence and progression.
Introduction: Studies have shown the reduction of CV events in patients with T2D treated GLP-1 RAs. However, little is known about how persistent use RA therapy affects outcomes and ASCVD. The objective this study was to estimate association between once weekly (OW) RAs 2-point MACE its components (MI, stroke) ASCVD a real-world setting. Methods: Adult ≥1 pharmacy claim for OW during Jan 2018-Nov 2022 were identified Optum Research Database. date first defined as index date. Patients...
Liraglutide and sitagliptin were compared on glycemic control all-cause healthcare costs over a 1-year period among older adults with type 2 diabetes (65–89 years) enrolled in national Medicare Advantage Prescription Drug health plan. This was retrospective study which the index date first prescription fill for liraglutide or between 25 January 2010 31 December 2014. Post-index treatment persistence glycosylated hemoglobin (HbA1c) at baseline 1 year (± 90 days) post-index required. Patients...
Long-term effectiveness and durability of glucose-lowering medications are important considerations in managing type 2 diabetes (T2D). This study aimed to compare treatment efficacy once-weekly (OW) semaglutide for T2D with that the dipeptidyl peptidase 4 inhibitor (DPP–4i) class. observational cohort used 2017–2022 data from Optum® Clinformatics® Data Mart long-term clinical outcomes associated or DPP–4i US adults T2D. The primary were HbA1c at 2-year follow-up, change baseline, odds...
Background: With OS’s FDA approval in September 2019, this study sought to provide real-world evidence on its effectiveness a cohort of early users.Methods: Claims and lab result data were used identify T2D patients who initiated OS between 09/20/19 - 10/31/20 (first claim date set as index). Selected had ≥1 HbA1c within both ≤3 months pre- ≥3 post-index ≥ 12 pre-index health plan eligibility. Study groups included: all patients, persistent (those with prescription 1.5 times days supply...